Lizhi (NASDAQ:LIZI) reported quarterly earnings of $0.05 per share. This is a 183.33 percent increase over losses of $(0.06) per share from the same period last year.
Prime Medicine and Myeloid Therapeutics Announce Settlement Of Pending Disputes, Signaling An End To The Pending Arbitrations And A Positive Outcome For Both Parties
Prime Medicine, Inc. (NASDAQ:PRME) ("Prime Medicine") and Myeloid Therapeutics, Inc. ("Myeloid"), today announced resolution of all of their outstanding disputes, signaling an end to the pending arbitrations and a
